Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Boehringer Ingelheim
AstraZeneca
Mallinckrodt
Baxter

Last Updated: May 19, 2022

Investigational Drug Information for MEDI4736


✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug MEDI4736?

MEDI4736 is an investigational drug.

There have been 349 clinical trials for MEDI4736. The most recent clinical trial was a Phase 3 trial, which was initiated on September 5th 2019.

The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Carcinoma. The leading clinical trial sponsors are AstraZeneca, MedImmune LLC, and National Cancer Institute (NCI).

There are forty-five US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for MEDI4736
TitleSponsorPhase
Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung CancerAstraZenecaPhase 2
Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung CancerWashington University School of MedicinePhase 2
Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast CancerAstraZenecaPhase 2

See all MEDI4736 clinical trials

Clinical Trial Summary for MEDI4736

Top disease conditions for MEDI4736
Top clinical trial sponsors for MEDI4736

See all MEDI4736 clinical trials

US Patents for MEDI4736

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
MEDI4736 See Plans and Pricing Synergistic combination of immunologic inhibitors for the treatment of cancer The University of Chicago (Chicago, IL) See Plans and Pricing
MEDI4736 See Plans and Pricing Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy MedImmune Limited (Cambridge, GB) See Plans and Pricing
MEDI4736 See Plans and Pricing Heterocyclic modulators of lipid synthesis 3-V Biosciences, Inc. (Menlo Park, CA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for MEDI4736

Drugname Country Document Number Estimated Expiration Related US Patent
MEDI4736 Canada CA2889182 2032-10-26 See Plans and Pricing
MEDI4736 European Patent Office EP2911669 2032-10-26 See Plans and Pricing
MEDI4736 World Intellectual Property Organization (WIPO) WO2014066834 2032-10-26 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Boehringer Ingelheim
AstraZeneca
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.